Audited Results
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indo Us Bio-Tech Limited reported standalone audited results for FY26. Revenue from Operations stood at Rs 539.65 Lakhs (vs Rs 1,104.91 Lakhs in FY25), representing a near 50% decline year-on-year. Profit before tax was Rs 1,302.02 Lakhs (down from Rs 1,653.00 Lakhs), with net profit at Rs 1,312.29 Lakhs (down from Rs 1,626.74 Lakhs). EPS declined to Rs 5.41 per share from Rs 8.11 previously. Total assets surged dramatically to Rs 7,330.87 Lakhs from Rs 978.43 Lakhs, primarily driven by inventory buildup of Rs 2,926.73 Lakhs. The auditor issued an unmodified opinion but included an Emphasis of Matter citing lack of confirmation on Trade Receivables, Trade Payables, Unsecured Loans, and inability to verify cash sales to farmers. Operating cash flow was deeply negative at Rs 1,258.08 Lakhs, raising concerns about cash generation despite profitability.
The sharp revenue decline and negative operating cash flow despite positive net profit signal potential earnings quality concerns. The large inventory buildup and unverifiable cash transactions add risk. Shareholders should monitor the company's ability to convert inventory to cash and clarify the significant asset growth.